Actively Recruiting
A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer
Led by National Cancer Centre, Singapore · Updated on 2025-06-12
600
Participants Needed
3
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the characteristics and clinical outcomes of advanced non-small cell lung cancer (NSCLC) patients in Asia who have a specific genetic change called EGFR exon 20 insertion mutation. This study aims to improve understanding of how different forms and locations of this mutation affect patient responses to new targeted therapies. It addresses a current gap in detailed knowledge about this condition in the Asian population. This is a multi-center observational study enrolling about 600 patients retrospectively from various countries across Asia, including Hong Kong, Korea, Singapore, Taiwan, and Thailand. Patients included have advanced NSCLC with confirmed EGFR exon 20 insertion mutations identified through approved local tests. The study does not involve experimental treatments but collects data on patients' clinical management and outcomes. Participants' medical records will be reviewed to gather information on survival, therapy durations, and disease progression over up to 10 years. The primary measures include overall survival, duration of therapy, and real-world progression-free survival. This long-term data collection will help researchers better understand the disease course and treatment effectiveness in this patient group.
CONDITIONS
Brief Title
A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed advanced NSCLC
- Positive test result for EGFR exon 20 insertion mutation by any locally approved test
- Diagnosis date between January 1, 2013 and December 31, 2024
- Male or female adults, age as defined by local regulations
You will not qualify if you...
- Patients without an EGFR exon 20 insertion mutation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants with advanced EGFR exon 20 insertion mutated NSCLC are observed over time to collect information on overall survival, duration of therapy, and progression-free survival.
Visits as per routine clinical care
Trial Site Locations
Total: 3 locations
1
National Cancer Centre, Singapore
Singapore, Singapore, 168583
Actively Recruiting
2
Seoul National University Hospital
Seoul, South Korea
Actively Recruiting
3
National Taiwan University Hospital
Taipei, Taiwan
Actively Recruiting
Research Team
C
Cherlyn Shepherdson
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here